NuvOx Pharma Awarded $1M Grant from National Cancer Institute

Desert Angels portfolio company, NuvOx Pharma; a biotechnology company based in Tucson, Arizona, has received a $1M grant from the National Cancer Institute (NCI) “Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma, (NCI Phase II SBIR, R44CA144817 – 02A1).” This grant comes less than a month after NuvOx was highlighted here for beginning Phase Ib clinical trial of its new drug — an oxygen-delivery agent — in patients with glioblastoma multiforme, a rare but particularly deadly form of brain cancer.

Click here for the full article